These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21792802)

  • 1. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C; Raymond E; Faivre S
    Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on systemic therapies of metastatic renal cell carcinoma.
    Herrmann E; Bierer S; Wülfing C
    World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
    Subbiah V; Slopis J; Hong DS; Ketonen LM; Hamilton J; McCutcheon IE; Kurzrock R
    J Clin Oncol; 2012 Feb; 30(5):e64-8. PubMed ID: 22203760
    [No Abstract]   [Full Text] [Related]  

  • 6. [Oncology 2008].
    Stemmler HJ; Heinemann V
    Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1395-9. PubMed ID: 18521794
    [No Abstract]   [Full Text] [Related]  

  • 7. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    Kibble A; Shumoogam J
    IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    Ravaud A
    Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
    J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapeutic agents and the skin: An update.
    Heidary N; Naik H; Burgin S
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal cell carcinoma].
    Obara W; Fujioka T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapy - point blank or single shot].
    Rübben H
    Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
    [No Abstract]   [Full Text] [Related]  

  • 16. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
    Cella D
    Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cutaneous side effects of antiangiogenic agents].
    Robert C
    Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.